Navigation Links
Clarus Ventures Closes $660 Million Fund
Date:2/25/2008

Brings assets under management to $1.2 billion

CAMBRIDGE, Mass. & SOUTH SAN FRANCISCO, Calif., Feb. 25 /PRNewswire/ -- Clarus Ventures, LLC ("Clarus Ventures"), a leading life sciences venture capital firm, announced today the single close of Clarus Lifesciences II, L.P. ("Clarus II"), a $660 million fund in Limited Partner commitments. This is the second investment fund formed and managed by Clarus Ventures, since the firm was established in 2005.

Clarus II will invest $20-60 million in biotechnology, specialty pharmaceutical and medical technology companies that are developing innovative products for the treatment of human diseases. The firm's first fund has committed 90 percent of its proceeds to date.

"We have effectively completed the deployment of our first fund and built a diversified portfolio of exciting companies," said Robert Liptak, a Clarus Ventures Managing Director. "These include companies with strong growth in revenue and profitability such as Globus Medical; products near commercialization such as Sientra, Pelikan, Oxford and Zogenix; and those with breakthrough products and technologies such as Aerovance, Centaurus, CoMentis, ESBATech, Pearl, ProActa, SarCode, Taligen, and Variation. We plan to follow a similar investment strategy for Clarus II. With the diversity and depth of our team we believe we can leverage our experience to identify and help grow leading companies in the life sciences field."

The Limited Partner base for Clarus II was effectively the same as in Clarus I. A small, select group of new high-quality investors who knew the firm well also participated.

The Clarus Ventures team is led by Nicholas Galakatos, Dennis Henner, Jeffrey Leiden, Robert Liptak, Nicholas Simon, Michael Steinmetz and Kurt Wheeler, an established group of investment professionals with deep and complementary backgrounds within the life sciences industry. The team uniquely balances broad investing expertise with leadership experience in major biotechnology and pharmaceutical companies.

About Clarus Ventures

Founded by a group of accomplished investment professionals with extensive and complementary industry backgrounds, Clarus Ventures is a life sciences venture capital firm with a team that has a long history of success in creating value. Internal operating experience combined with longstanding relationships with key opinion leaders and industry thought leaders and decision makers allow this team to identify unique investment opportunities and shepherd them to maturity. Clarus Ventures augments its core expertise of investing in biopharmaceuticals and medical technology with deep and diverse expertise in research and development, commercialization, business development and operations management at the global level. The firm has $1.2 billion under management and has offices in Cambridge, Mass., and South San Francisco, CA.

For additional information on Clarus Ventures, please visit http://www.clarusventures.com.

CONTACTS:

Nicholas Galakatos, Ph.D., Clarus Ventures, Tel.: 617-949-2223

Robert Liptak, Clarus Ventures, Tel.: 617-694-2222

Tony Russo, Russo Partners, Tel.: 212-845-4251


'/>"/>
SOURCE Clarus Ventures, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
2. Jerusalem Global Ventures Announces $200 Million Growth Equity Fund
3. Khosla Ventures and BIOeCON Form KiOR Inc.
4. Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence
5. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
6. Dan Broderick Joins Prolog Ventures as Partner
7. Hank Plain Joins Morgenthaler Ventures as Partner
8. Ocera Therapeutics Closes $35.5 Million Series C Financing
9. Sinovac Closes $9.75 Million Private Placement
10. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
11. Progentix Orthobiology B.V. Closes Series A Financing Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... ... today announced that the stock market news outlet had initiated coverage on ... testing that screens and identifies exposure, progression and risk analysis from specific ...
(Date:7/20/2017)... ... July 20, 2017 , ... VIC Technology Venture Development™ (VIC™), is ... directors. This addition continues to strengthen and diversify VIC’s board. , "We are ... “He is a highly accomplished business executive with a broad range of experience directly ...
(Date:7/18/2017)... ... July 18, 2017 , ... ... pharmaceutical and biotherapeutics development, announces the launch of a new NTA biosensor chip ... enables researchers to study the kinetics of polyhistidine-tagged (His-tagged) molecules quickly and reliably. ...
(Date:7/18/2017)... ... July 18, 2017 , ... Allotrope Foundation won the ... phase of the Allotrope Framework for commercial use. , The Bio-IT World Best ... only elevate the critical role of information technology in modern biomedical research, but ...
Breaking Biology Technology:
(Date:5/6/2017)... , May 5, 2017 RAM ... announced a new breakthrough in biometric authentication based ... quantum mechanical properties to perform biometric authentication. These new ... semiconductor material created by Ram Group and its ... entertainment, transportation, supply chains and security. Ram Group ...
(Date:4/18/2017)... SUNNYVALE, Calif. , April 18, 2017  Socionext Inc., a ... prototype of a media edge server, the M820, which features the ... face recognition software provided by Tera Probe, Inc., will be showcased ... and at the NAB show at the Las Vegas ... ...
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):